Quality of life in patients with cancers of the upper gastrointestinal tract

References

• Fallowfield L.J. The Quality of Life: The Missing Measurement in Health Cam Souvenir Press Ltd, London, UK, (1990).
   Google Scholar
• Sloan JA, Loprinzi CL, Kuross SA et al Randomised comparison of four tools measuring overall quality of life in patients with advanced cancer. j Gun. Oncol 17, 738–740 (1998).
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. Natl Cancer Inst. 85,365-376 (1993). The EORTC QLQ-C30 core questionnaire contains 30 items addressing functional aspects of QOL and symptoms that commonly occur in patients with cancer. Excellent psychometric data support its credibility and it has been tested in many different cancer sites and treatment groups.
   Google Scholar
• Cella DF, Tulsky DS, Gray G et al The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure.J Gun. Oncol 11,570–579 (1993).
   Google Scholar
• •The FACT-G general QOL measurecontains 28 items addressing functional aspects of QOL and symptoms. Excellent psychometric data support its use in patients with cancer, it may also be used in patients with nonmalignant chronic disease.
   Google Scholar
• Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health related quality of life measures: literature review and proposed guidelines j Gun. Epidemiol 46,1417–1432 (1993).
   Google Scholar
• Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Exp. Cancer Ther. Macleod CM (Ed.), Columbia University Press, New York, USA, 191–205 (1949).
   Google Scholar
• World Health Organisation. World Health Organisation handbook for reporting
   Google Scholar
• •• results of cancer treatment. WHO, Geneva, Switzerland (1979).
   Google Scholar
• McLarty AJ, Deschamps C, Trastek VF, Allen MS, Pairolero PC, Harmsen WS. Esophageal resection for cancer of the esophagus: Long-term function and quality of life. Ann. Thorac. Surg. 63,1568–1572 (1997).
   PubMed Web of Science ®Google Scholar
• Eypasch E, Williams JI, Wood-Dauphinee S et al. Gastrointestinal quality of life index: development, validation and application of a new instrument. BE j Surg. 82,216–222 (1995).
   PubMed Web of Science ®Google Scholar
• Kemmler G, Holzner B, Kopp M et al. Comparison of two quality of life instruments for cancer patients: The Functional Assessment of Cancer Therapy-General and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. I Clin. °nevi 17,2932–2940 (1999).
   Google Scholar
• Blazeby JM, Alderson D, Winstone K eta]. Development of a EORTC questionnaire module to be used in quality of life assessment for patients with esophageal cancer. Eur. Cancer32, 1912–1917 (1996).
   Google Scholar
• •The EORTC QLQ-0ES24 has been designed for patients with local and advanced esophageal cancer undergoing treatment with curative or palliative intent including surgery, chemotherapy, radiotherapy and/or endoscopic palliation. Full psychometric data will be available soon.
   Google Scholar
• Fitzsimmons D, Johnson CD, George S et al Development of a disease specific quality of life questionnaire module to supplement the EORTC core cancer quality of life questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur j Cancer 35, 939–941 (1999).
   PubMedGoogle Scholar
• •The EORTC QLQ-Pan26 is designed for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy.
   Google Scholar
• Vickery CW, Blazeby JM, Conroy T et al on behalf of the EORTC Quality of Life Group: Development of an EORTC disease specific quality of life module for use in patients with gastric cancer. Eur. j Cancer 37,966–971(2001).
   PubMed Web of Science ®Google Scholar
• •The EORTC QLQ-ST022 is designed to use among a wide range of patients with gastric adenocarcinoma undergoing surgery with or without neoadjuvant or adjuvant chemoradiotherapy. It may also be used in patients receiving palliative treatment.
   Google Scholar
• Cella D. The Functional Assessment with Chronic Illness Manual. FACIT Manual. (1997).
   Google Scholar
• ••The FACIT system of QOL assessmentprovides a general measure with additional scales for over 20 different diseases (both benign and malignant). The comprehensive manual explains scoring procedures as well as how to deal with missing data.
   Google Scholar
• Thybusch-Bernhardt A, Schmidt C, Kuchler T, Schmid A, Henne-Bruns D, Kremer B. Quality of life following radical surgical treatment of gastric carcinoma. Worldj Surg. 233,503–598 (1999).
   Google Scholar
• Troidl H, Kusche J, Vestweber KH, Eypasch E, Maul U. Pouch versus esophagojejunostomy after total gastrectomy: a randomised clinical trial. Worldj Surg. 11,699–712 (1987).
   PubMed Web of Science ®Google Scholar
• Zieren HU, Jacobi CA, Zieren J, Muller JM. Quality of life following resection of esophageal carcinoma. BE j Surg. 83, 1772–1775 (1996).
   PubMed Web of Science ®Google Scholar
• Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal cancer. Cancer 88, 1781–1787 (2000).
   PubMed Web of Science ®Google Scholar
• de Boer AGEM, Genovesi PIO, Sprangers MAG, van Sandick JW, Obertop H, van Lanshot JJB. Quality of life in long-term survivors after curative transhiatal esophagectomy for esophageal carcinoma. Br. Surg. 87,1716–1721 (2000).
   Google Scholar
• Reed CE, Marsh WH, Carlson LS, Seymore CH, Kratz JM. Prospective, randomised trial of palliative treatment for unresectable cancer of the esophagus. Ann. Thorac. Surg. 51,552–556 (1991).
   Google Scholar
• Fuchs KH, Freys SM, Schaube H, Eckstein AK, Selch A, Hamelmann H. Randomised comparison of endoscopic palliation of malignant esophageal stenoses. Surg. Enclosc. 5,63–67 (1991).
   PubMedGoogle Scholar
• Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl. I Merl 329,1302–1307 (1993).
   Google Scholar
• OHanlon D, Harkin M, Daya K, Sergeant T, Hayes N, Griffin SM. Quality of life assessment in patients undergoing treatment for esophageal carcinoma. BE J: Surg. 82,1682–1685 (1995).
   PubMedGoogle Scholar
• Mellow MH, Pinkas H. Endoscopic laser therapy for malignancies affecting the esophagus and gastresophageal junction. Arch. Int. Med. 145,1443–1446 (1985).
   PubMedGoogle Scholar
• Rutgeerts P, Vantrappen G, Broeckaert L et al Palliative Nd:YAG laser therapy for cancer of the esophagus and gastresophageal junction: impact on the quality of remaining life. Castrointest. Enclosc. 34,87–89 (1988).
   PubMedGoogle Scholar
• Barr H, Krasner N, Raouf A, Walker RJ. Prospective randomised trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia. Gut 31,252–258 (1990).
   PubMed Web of Science ®Google Scholar
• Mathus-Vliegen EMH, Tytgat GNJ. Palliation by laser photoablation: a multidisciplinary quality assessment. Castrointest. Enclosc. 38,365-368 (1992).
   Google Scholar
• Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72,37–41 (1993).
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. BE J: Cancer71, 587–591 (1995).
   Google Scholar
• Webb A, Cunningham D, Scarffe JH et al. Randomised trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methrotrexate in advanced esophagogastric cancer. 1 Clin. awl 15,261–267 (1997).
   Google Scholar
• Ilson DH, Saltz L, Enzinger P eta]. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. j Clin. Oncol 17,3270–3275 (1999).
   Google Scholar
• Svedlund J, Sullivan M, Sjodin I, Liedman B, Lundell L. Quality of life in gastric cancer prior to gastrectomy. Quality of Life Res. 5,255–264 (1996).
   Google Scholar
• Koster R, Gebbensleben B, Stutzer H, Salzberger B, Ahrens P, Rhode H. Quality of life in gastric cancer. Scancl Castroenterol 22 (Suppl. 133), 102–106 (1987).
   Google Scholar
• Visick AH. A study of the failures after gastrectomy. Ann. R. Coll Surg. Engl. 3, 266–284 (1948).
   PubMed Web of Science ®Google Scholar
• Davies J, Johnston D, Sue-Ling HM, Young S, May J, Griffith J. Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. World J. Surg. 22,1048–1055 (1998).
   Google Scholar
• Jentschura D, Winkler M, Strohmeier N, Rumstadt B, Hagmuller E. Quality of life after gastrectomy for gastric carcinoma: a comparison between total gastrectomy and subtotal gastric resection. HepatoCastroenterology44, 1137–1142 (1997).
   PubMedGoogle Scholar
• Buhl K, Schlag P, Herfarth C. Quality of life and functional results following different types of resection for gastric carcinoma. Eur. Surg. Oiled 16, 404–409 (1990).
   Google Scholar
• Thiede A, Fuchs KH, Hamelman H. Pouch and roux-en-Y reconstruction after gastrectomy. Airh. Surg: 122, 837–842 (1987).
   Google Scholar
• Buhl K, Lehnert T, Herfarth C. Reconstruction after gastrectomy and quality of life. World J. Surg: 19, 558–564 (1995).
   Google Scholar
• Svedlund J, Sullivan M, Liedman B, Lundell L. Long term consequences of gastrectomy for patient's quality of life: the impact of reconstructive techniques. Am. Castroenterol 94, 438–445 (1999).
   PubMed Web of Science ®Google Scholar
• Fuchs KH, Thiede A, Engemann R, Deltz E, Stemme 0, Hamelmann H. Reconstruction of the food passage after total gastrectomy: randomised trial. World Surg. 19, 698–706 (1995).
   Google Scholar
• Zieren HU, Zippel K, Zieren J, Muller JM. Quality of life after surgical treatment of gastric carcinoma. Eur Surg. 164, 119–125 (1998).
   Google Scholar
• Glimelius B, Ekstrom K, Hoffman K eta]. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oiled 8, 163–168 (1997).
   Google Scholar
• Ebert M, Friess H, Beger H, Buchler M. Role of octreotide in the treatment of pancreatic cancer. Digestion 55, 48–51 (1994).
   PubMedGoogle Scholar
• Kasen D, Portenoy RK, Thaler HT, Niedzwiecki D, Passik S. Pain and depression in patients with newly diagnosed pancreas cancer. J: Clin. Oncol 13, 748–755 (1995).
   Google Scholar
• Ballinger AB, McHugh M, Catnach SM, Alstead EM, Clark ML. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut 35, 467–470 (1994).
   Google Scholar
• Glimelius B, Hoffman JP, Sjoden PO eta]. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol 7, 593–600 (1996).
   Google Scholar
• McLeod R, Taylor B, O'Connor B et al. Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure. Am J: Surg. 169, 179–185 (1995).
   PubMedGoogle Scholar
• Nieveen van Dijkum E, Terwee C, Oosterveld P, van der Meulen J, Gouma D, De Jong PL. Validation of the gastrointestinal quality of life index for patients with potentially operable periampullary carcinoma. BE J: Surg. 87, 110–115 (2000).
   PubMedGoogle Scholar
• Revicki DA, Cella D. Health status assessment for the twenty first century: item response theory, item banking and computer adaptive testing. Quality of Life Res. 6, 595–600 (1997).
   PubMed Web of Science ®Google Scholar
• Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The Sickness Impact Profile: validation of a health status measure. Med. Carr 14, 57–67 (1976).
   Google Scholar
• Baum M, Ebbs SR, Fallowfield LJ, Fraser SCA. Measurement of quality of life in advanced breast cancer. Acta Oncologica 29, 391–395 (1990).
   PubMed Web of Science ®Google Scholar
• Dancey J, Dee B, Osoba D et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving variable. Quality of Life Res. 6, 151–158 (1997).
   PubMed Web of Science ®Google Scholar
• Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients. As an important prognostic factor. Lung Cancer 31, 233–240 (2001).
   PubMed Web of Science ®Google Scholar
• Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health survey manual and interpretation guide. New England Medical Centre, Boston, USA, (1993).
   Google Scholar
• Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R et al. Measuring the quality of life of cancer patients. A concise QL-index for use by physicians. J: Chron. Dis. 34, 585–597 (1981).
   Google Scholar
• de Haes JCJM, van Knippenberg FCE, Neijt JR Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. BE J: Cancer 62, 1034–1038 (1990).
   Google Scholar
• Roder JD, Herschbach P, Sellschopp A, Siewert JR. Quality-of-life assessment following esophagectomy. Theoret. Surg. 6, 206–210 (1991).
   Google Scholar
• van Knippenberg FCE, Out JJ, Tilanus HW, Mud HJ, Hop WCJ, Verhage F. Quality of life in patients with resected esophageal cancer. Social Sci. Med. 35, 139–145 (1992).
   PubMedGoogle Scholar
• Farndon MA, Wayman J, Clague MB, Griffin SM. Cost-effectiveness in the management of patients with esophageal cancer. Br. Surg. 85, 1394–1398 (1998).
   PubMedGoogle Scholar
• Brunelli C, Mosconi P, Boeri P eta]. Evaluation of quality of life in patients with malignant dysphagia. Tumor] 86, 134–138 (2000).
   Google Scholar
• Kusche J, Westweber KH, Troidl H. Quality of life after total gastrectomy for stomach cancer. Results of three types of quality of life evaluative methods. Scant J: Castroenterol 22, 96–101 (1987).
   Google Scholar
• Pietrabissa A, Vistoli F, Carobbi A, Boggi U, Bisa M, Mosca E Thoracopic splanchnicectomy for pain relief in unresectable pancreatic cancer. Airh. Surg. 135, 332–335 (2000).
   PubMedGoogle Scholar